TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
RALEIGH, N.C., Aug. 21, 2017 -- INC Research/inVentiv Health (Nasdaq:INCR), the only fully-integrated biopharmaceutical solutions organization, today announced that Chief Financial Officer Greg Rush is scheduled to present at two upcoming investor conferences.
Mr. Rush is scheduled to present during the 2017 Wells Fargo Healthcare Conference in Boston, MA, on Wednesday, September 6, 2017, at 8:30 a.m. EDT.
Mr. Rush is scheduled to present during the 2017 Robert W. Baird Global Healthcare Conference in New York, NY, on Thursday, September 7, 2017, at 2:00 p.m. EDT.
Links to INC/inVentiv’s live presentation and archived audio replay, as well as the presentation materials, will be available via the Company’s Investor Relations website at investor.incresearch.com.
About INC Research/inVentiv Health
INC Research/inVentiv Health (Nasdaq:INCR) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to address new market realities where clinical and commercial share expertise, data and insights to accelerate biopharmaceutical performance. With more than 22,000 employees and the ability to support customers in more than 110 countries, our global scale and deep therapeutic alignment enables INC Research/inVentiv Health to help customers successfully navigate an increasingly complex environment. For more information on our Raleigh, N.C.-based company, visit incresearch.com or inventivhealth.com.
Investor Relations Contact: Ronnie Speight Vice President, Investor Relations +1 919 745 2745 [email protected] Press/Media Contact: Danielle DeForge Senior Director, External Communications +1 781 425 2624 [email protected]
